首页> 外文期刊>The Journal of molecular diagnostics: JMD >ChildSeq-RNA: A next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas
【24h】

ChildSeq-RNA: A next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas

机译:ChildSeq-RNA:一种基于下一代测序的诊断方法,可鉴定儿童肉瘤中已知的融合转录本

获取原文
获取原文并翻译 | 示例
           

摘要

Childhood sarcomas can be extremely difficult to accurately diagnose on the basis of morphological characteristics alone. Ancillary methods, such as RT-PCR or fluorescence in situ hybridization, to detect pathognomonic gene fusions can help to distinguish these tumors. Two major deficiencies of these assays are their inability to identify gene fusions at nucleotide resolution or to detect multiple gene fusions simultaneously. We developed a next-generation sequencing-based assay designated ChildSeq-RNA that uses the Ion Torrent platform to screen for EWSR1-FLI1 and EWSR1-ERG, PAX3-FOXO1 and PAX7-FOXO1, EWSR1-WT1, and ETV6-NTRK3 fusions of Ewing sarcoma (ES), alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and congenital fibrosarcoma, respectively. To rapidly analyze resulting data, we codeveloped a bioinformatics tool, termed ChildDecode, that operates on a scalable, cloud-computing platform. Total RNA from four ES cell lines plus 33 clinical samples representing ES, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and congenital fibrosarcoma tumors was subjected to ChildSeq-RNA. This accurately identified corresponding gene fusions in each tumor type, with no examples of false positive fusion detection in this proof-of-concept study. Comparison with previous RT-PCR findings demonstrated high sensitivity (96.4%; 95% CI, 82.3%-99.4%) and specificity (100%; 95% CI, 56.6%-100%) of ChildSeq-RNA to detect gene fusions. Herein, we propose ChildSeq-RNA as a novel tool to detect gene fusions in childhood sarcomas at single-nucleotide resolution.
机译:仅根据形态学特征很难准确诊断儿童肉瘤。 RT-PCR或荧光原位杂交等辅助方法可检测病原基因融合,可帮助区分这些肿瘤。这些测定法的两个主要缺陷是它们不能以核苷酸分辨率鉴定基因融合体或不能同时检测多个基因融合体。我们开发了下一代基于测序的测定法,命名为ChildSeq-RNA,该测定法使用离子激流平台筛选Ewing的EWSR1-FLI1和EWSR1-ERG,PAX3-FOXO1和PAX7-FOXO1,EWSR1-WT1和ETV6-NTRK3融合蛋白肉瘤(ES),肺泡横纹肌肉瘤,增生性小圆形细胞瘤和先天性纤维肉瘤。为了快速分析结果数据,我们共同开发了一种称为ChildDecode的生物信息学工具,该工具可在可扩展的云计算平台上运行。对来自四个ES细胞系的总RNA以及代表ES,肺泡横纹肌肉瘤,增生性小圆形细胞瘤和先天性纤维肉瘤肿瘤的33个临床样品进行ChildSeq-RNA处理。这可以准确识别每种肿瘤类型中的相应基因融合体,在该概念验证研究中没有假阳性融合体检测的例子。与以前的RT-PCR结果比较表明,ChildSeq-RNA的高灵敏度(96.4%; 95%CI,82.3%-99.4%)和特异性(100%; 95%CI,56.6%-100%)可检测基因融合体。在这里,我们提出ChildSeq RNA作为一种新型工具,以单核苷酸分辨率检测儿童肉瘤中的基因融合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号